# A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

> **NCT05574166** · PHASE1 · TERMINATED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Atherosclerosis
- Ischemic Stroke

## Interventions

- **DRUG:** SP-8356
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05574166
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-03
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-10-29
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Only Part 1 was conducted but not Part 2. Due to the low exposures, definitive safety conclusions could not be made for the targeted exposure levels in the future.
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05574166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05574166, "A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05574166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*